Icon

VANFLYTA (NDA216993)- (EQ 17.7MG BASE,EQ 26.5MG BASE)

QUIZARTINIB DIHYDROCHLORIDE DAIICHI SANKYO INC
EQ 17.7MG BASE,EQ 26.5MG BASE
No No
2033-Sep-30 2028-Jul-20
None None
None No
VANFLYTA is a kinase inhibitor indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test.
0 0 0
Total Other Developers None
Drugs with Suitability No
EQ 17.7MG BASE ** ** - - -
EQ 26.5MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.